Deadly fungus and companies with potential treatment

  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 53%

Business News News

Business Business Latest News,Business Business Headlines

The U.S. Food and Drug Administration approved Cidara Therapeutics and Melinta Therapeutics' antifungal drug for patients with little to no other options.

Novavax President and CEO Stanley Erck says the recently CDC-approved vaccine has shown great efficacy and is a 'bit more stable' than other immunizations on 'Cavuto: Coast to Coast.'to help patients with limited or no other treatment options.What is Rezzayo?

Both of these infections can be caused by a number of Candida species, including Candida auris , which started to spread at an alarming rate across U.S. health care facilities in the early days of the COVID-19 pandemic. Although Rezzayo was only approved for adults with limited or no alternative treatment options, its approval marked a major medical milestone, according to Cidara CEO Jeffrey Stein.

Candida auris is a yeast responsible for many infections. Resistant to most antifungal drugs, this fungus causes several deaths worldwide.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Not buying this fear mongering.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 458. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines